US Stock MarketDetailed Quotes
VSTM Verastem
- 2.4700
- -0.1400-5.36%
Close Aug 27 16:00 ET
99.40MMarket Cap-769P/E (TTM)
2.6000High2.4200Low489.50KVolume2.5900Open2.6100Pre Close1.22MTurnover1.22%Turnover RatioLossP/E (Static)40.24MShares14.220052wk High5.28P/B99.00MFloat Cap2.100052wk Low--Dividend TTM40.08MShs Float225.8400Historical High--Div YieldTTM6.90%Amplitude2.1000Historical Low2.4890Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Verastem Stock Forum
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed ...
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 ...
Verastem Oncology, a biopharmaceutical company listed on Nasdaq under the ticker VSTM, has recently announced the commencement of dosing for the first patient in a Phase 1/2 clinical trial in China. This trial, conducted by GenFleet Therapeutics, aims to evaluate GFH375/VS-7375, a novel KRAS G12D (ON/OFF) inhibitor. $Verastem (VSTM.US)$
...
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375...
储亿银行维持Verastem(VSTM.US)买入评级，目标价18美元
No comment yet